{"id":"cpt-11-5-fu-and-l-lv","safety":{"commonSideEffects":[{"rate":"46%","effect":"Diarrhea"},{"rate":"34%","effect":"Fatigue"},{"rate":"29%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CPT-11 (irinotecan) works by inhibiting topoisomerase I, an enzyme involved in DNA replication and transcription. This leads to DNA damage and ultimately cell death in rapidly dividing cancer cells.","oneSentence":"Topoisomerase I inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:30.577Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT06733038","phase":"PHASE3","title":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-11-15","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT03493048","phase":"PHASE2","title":"Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-04-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":146},{"nctId":"NCT01835041","phase":"PHASE1","title":"CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-04","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":21},{"nctId":"NCT00098787","phase":"PHASE2","title":"Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-09-08","conditions":"Colorectal Cancer","enrollment":247},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT02497157","phase":"PHASE2","title":"Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2015-05-21","conditions":"Metastatic Colorectal Cancer","enrollment":45},{"nctId":"NCT00079274","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-02","conditions":"Adenocarcinoma of the Colon, Stage III Colon Cancer","enrollment":3397},{"nctId":"NCT01643499","phase":"PHASE1","title":"Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-03-26","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary","enrollment":79},{"nctId":"NCT01996306","phase":"PHASE3","title":"A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC","status":"COMPLETED","sponsor":"Epidemiological and Clinical Research Information Network","startDate":"2013-12-02","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms","enrollment":650},{"nctId":"NCT00068692","phase":"PHASE3","title":"Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-10-15","conditions":"Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma","enrollment":225},{"nctId":"NCT03222089","phase":"PHASE2","title":"Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC","status":"WITHDRAWN","sponsor":"Fujian Cancer Hospital","startDate":"2017-07-20","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03303495","phase":"PHASE3","title":"A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2011-11-14","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms","enrollment":280},{"nctId":"NCT02246049","phase":"PHASE2","title":"A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2014-05","conditions":"Colorectal Neoplasms","enrollment":69},{"nctId":"NCT01413022","phase":"PHASE1","title":"FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-04","conditions":"Pancreatic Neoplasms","enrollment":44},{"nctId":"NCT01320683","phase":"PHASE2","title":"Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2011-03","conditions":"Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer","enrollment":1},{"nctId":"NCT00005036","phase":"PHASE3","title":"Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-11","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":560},{"nctId":"NCT00284258","phase":"PHASE2, PHASE3","title":"Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2006-01","conditions":"Colorectal Cancer","enrollment":426},{"nctId":"NCT00209625","phase":"PHASE1, PHASE2","title":"Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2000-04","conditions":"Colorectal Cancer","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CPT-11, 5-FU and l-LV","genericName":"CPT-11, 5-FU and l-LV","companyName":"Taiho Pharmaceutical Co., Ltd.","companyId":"taiho-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topoisomerase I inhibitor Used for Colorectal cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}